Goldman Sachs Resumes Alexion Pharmaceuticals (ALXN) at Buy, Says Opportunity Underestimated
Tweet Send to a Friend
Goldman Sachs resumes coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with a Buy rating and $120 price target, suggesting 26 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
